<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01929265</url>
  </required_header>
  <id_info>
    <org_study_id>IIL INFL09</org_study_id>
    <nct_id>NCT01929265</nct_id>
  </id_info>
  <brief_title>A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma</brief_title>
  <acronym>IIL INFL09</acronym>
  <official_title>A Phase II Study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Italiana Linfomi ONLUS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Italiana Linfomi ONLUS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter phase II trial designed to determine efficacy and safety&#xD;
      of a chemoimmunotherapy with the combination of Bendamustine + Rituximab in patients with&#xD;
      advanced untreated Indolent non Follicular non-Hodgkin Lymphomas (INFL).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter phase II trial designed to determine efficacy and safety&#xD;
      of a chemoimmunotherapy with the combination of Bendamustine + Rituximab in patients with&#xD;
      advanced untreated Indolent non Follicular non-Hodgkin Lymphomas (INFL).&#xD;
&#xD;
      The study includes and induction phase and a consolidation phase.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission rate (CR)</measure>
    <time_frame>5 months</time_frame>
    <description>Evaluated at the end of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety analysis</measure>
    <time_frame>5 months</time_frame>
    <description>Evaluated during and at the end of treatment. Percentage of patients with adverse, hematological and non-hematological toxic events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>5 months</time_frame>
    <description>Evaluated at the end of treatment. Complete plus partial remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>at 2 years</time_frame>
    <description>Dead for any causes after diagnosis. Evaluated by means of Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>at 2 years</time_frame>
    <description>Progression, relapse or dead for any causes after diagnosis. Evaluated by means of Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (PFS)</measure>
    <time_frame>at 2 years</time_frame>
    <description>Relapse or dead for any causes from the end of treatment, for patients in CR after B+R. Evaluated by means of Kaplan-Meier method.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Indolent Non-follicular</condition>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>Rituximab - Bendamustine (RB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 arm: Rituximab - Bendamustine (RB)&#xD;
1 arm for all patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>INDUCTION PHASE&#xD;
Rituximab - Bendamustine (RB): cycles 1 to 4 (0, 4, 8, 12 week):&#xD;
Rituximab: 375 mg/sqm iv, day 1*&#xD;
Bendamustine: 90 mg/sqm iv, days 1-2 or days 2-3 according to istitutional/patient/physician choice&#xD;
Repeat cycles every 28 days for a total of 4 cycles&#xD;
*In cycle 1, in order to avoid tumor lysis syndrome, Rituximab will be given on day 8.&#xD;
CONSOLIDATION PHASE&#xD;
Rituximab - Bendamustine (RB): cycles 5 to 6 (16, 20 week):&#xD;
Rituximab: 375 mg/sqm iv day 1&#xD;
Bendamustine: 90 mg/sqm iv days 1-2 or days 2-3 according to istitutional/patient/physician choice&#xD;
Rituximab two monthly doses&#xD;
Rituximab: 375 mg/sqm iv week 24 and 28</description>
    <arm_group_label>Rituximab - Bendamustine (RB)</arm_group_label>
    <other_name>RIBOMUSTIN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Understand and voluntarily sign an informed consent form&#xD;
&#xD;
          2. Histological (bone marrow or lymph nodes biopsy) proven diagnosis of B-cell CD20-&#xD;
             positive non-follicular NHL according to REAL/WHO Classification:&#xD;
&#xD;
             i. small lymphocytic lymphoma-SLL (bone marrow or lymph nodes biopsy ii.&#xD;
             lymphoplasmacytic/citoid lymphoma/ Waldenstrom macroglobulinemia(bone marrow or lymph&#xD;
             nodes biopsy) iii. nodal marginal zone lymphoma (lymph nodes biopsy)&#xD;
&#xD;
          3. Untreated patients&#xD;
&#xD;
          4. Stage III or IV or stage II with more than three involved sites&#xD;
&#xD;
          5. Presence of at least one of the following criteria for the definition of active&#xD;
             disease:&#xD;
&#xD;
               1. Systemic symptoms&#xD;
&#xD;
               2. Hemoglobin less than 10 g/dL (due to lymphoma)&#xD;
&#xD;
               3. Platelets less than 100 x 10 9/L (due to lymphoma)&#xD;
&#xD;
               4. Diffuse bone marrow infiltrate&#xD;
&#xD;
               5. Lymphocyte doubling time less than 12 months (in leukemic cases)&#xD;
&#xD;
               6. Bulky disease (&gt;7 cm)&#xD;
&#xD;
          6. Aged 18 - 75 Life expectancy &gt;6 months&#xD;
&#xD;
          7. ECOG performance status 0-2&#xD;
&#xD;
          8. LVEF ≥45% or FS ≥37%&#xD;
&#xD;
          9. ANC ≥1 x 10 9/l and Platelets count ≥75 x 10 9/l, unless due to bone marrow&#xD;
             involvement by follicular lymphoma&#xD;
&#xD;
         10. Creatinine up to 1.5 x ULN&#xD;
&#xD;
         11. Conjugated bilirubin up to 2 x ULN&#xD;
&#xD;
         12. Alkaline phosphatase and transaminases up to 2 x ULN&#xD;
&#xD;
         13. Written informed content&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with diagnosis of marginal zone lymphoma of splenic or MALT origin&#xD;
&#xD;
          2. Patients with diagnosis of typical Chronic Lymphocytic Leukemia (CLL)&#xD;
&#xD;
          3. Men not agreeing to take adequate contraceptive precautions during and for at least 6&#xD;
             months after cessation of therapy&#xD;
&#xD;
          4. History of other malignancies within 3 years prior to study entry except for:&#xD;
             adequately treated carcinoma in situ of the cervix; basal or squamous cell skin&#xD;
             cancer; low grade, early stage, localized prostate cancer treated surgically with&#xD;
             curative intent; good prognosis DCIS of the breast treated with lumpectomy alone with&#xD;
             curative intent&#xD;
&#xD;
          5. Medical condition requiring long term use (&gt;1 months) of systemic corticosteroids&#xD;
&#xD;
          6. Active bacterial, viral, or fungal infection requiring systemic therapy&#xD;
&#xD;
          7. Concurrent medical condition which might exclude administration of therapy&#xD;
&#xD;
          8. Cardiac insufficiency (NYHA grade III/IV)&#xD;
&#xD;
          9. Myocardial infarction within 6 months of entry on study&#xD;
&#xD;
         10. Severe chronic obstructive pulmonary disease with hypoxemia&#xD;
&#xD;
         11. Severe diabetes mellitus difficult to control with adequate insulin therapy&#xD;
&#xD;
         12. Hypertension that is difficult to control&#xD;
&#xD;
         13. Impaired renal function with creatinine clearance &lt;30 ml/min&#xD;
&#xD;
         14. HIV positivity&#xD;
&#xD;
         15. HBV positivity with the exception of patients HbsAg negative and Ab anti-Hbcore&#xD;
             positive(these patientes need to receive prophylaxis with Lamivudine)&#xD;
&#xD;
         16. HCV positivity with the exception of patients with HCV RNA negative.&#xD;
&#xD;
         17. CNS involvement by lymphoma&#xD;
&#xD;
         18. Participation at the same time in another study in with investiogational drugs are&#xD;
             used&#xD;
&#xD;
         19. Known hypersensitivity or anaphylactic reactions to murine antibodies or proteins&#xD;
&#xD;
         20. Any other co-existing medical or psychological condition that would preclude&#xD;
             participation in the study or compromise ability to give informed consent&#xD;
&#xD;
         21. Women in pregnancy or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luca Baldini, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UOC Ematologia 1/CTMO, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SC Ematologia - AO SS. Antonio e Biagio e C. Arrigo</name>
      <address>
        <city>Alessandria</city>
        <state>AL</state>
        <zip>15121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Ematologia Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia e Trapianti, Ospedale San Maurizio</name>
      <address>
        <city>Bolzano</city>
        <state>BZ</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia, Centro Trapianto di Cellule Staminali</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <state>Foggia</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione Ematologia I , Ospedale San Martino</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Ematologia Azienda Ospedaliera Papardo</name>
      <address>
        <city>Messina</city>
        <state>ME</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Oncologia Medica ed Ematologia, Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Ospedale Niguarda</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Modenese</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia Azienda Ospedaliero Universitaria Paolo Giaccone</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Div. Oncologia Medica - CRO, Centro di Riferimento Oncologico</name>
      <address>
        <city>Aviano</city>
        <state>PN</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOC Ematologia 1/CTMO, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncoematologia Istituto Pascale</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C.D.U Ematologia Azienda Ospedaliero Universitaria Maggiore</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Ematologia Università - Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia Ospedale Santo Spirito</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOA Ematologia, Ospedale Civile Ospedale G. da Saliceto</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Div. Ematologia AO Bianchi Melacrino Morelli</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia, Azienda Ospedaliera Arcispedale &quot;S.Maria Nuova&quot;</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia, Università &quot;La Sapienza&quot;</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologia Policlino Le Scotte</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Struttura Complessa di Onco-Ematologia Azienda Ospedaliera S.Maria</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Ematologia - Città della Salute e della Scienza</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Ematologia U - Città della Salute e della Scienza</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica e Unità di Terapie Cellulari 'Carlo Melzi' AOU S. Maria della Misericordia</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>August 22, 2013</study_first_submitted>
  <study_first_submitted_qc>August 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2013</study_first_posted>
  <last_update_submitted>October 12, 2017</last_update_submitted>
  <last_update_submitted_qc>October 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>INFL</keyword>
  <keyword>Indolent non-follicular</keyword>
  <keyword>untreated INFL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

